Highlight
Patients with metastatic castration‑resistant prostate cancer (mCRPC) treated with lutetium‑177 PSMA radioligand therapy ([177Lu]Lu‑PSMA) show markedly higher PSA responses and objective response rates and a robust reduction in radiographic progression risk; no statistically significant overall survival (OS) benefit was observed in the pooled randomized evidence, and grade ≥3 adverse events were not increased.
